Survey of Challenges in Access to Diagnostics and Treatments for Net Patients

We SCAN! – An Alliance of 26 Neuroendocrine Tumour Patient Groups Across 6 Continents Launches the First-Ever Global Survey to Measure the Access Challenges to Optimal NET Care

SCAN is an acronym standing for Survey of Challenges in Access to Diagnostics and Treatment for NET Patients. It aims to collect robust global data and answer key questions related to awareness and availability of NET diagnostics and treatments worldwide versus the out-of-pocket costs for those living with NETs.

Under the motto We SCAN, the International Neuroendocrine Cancer Alliance invites NET patients and their carers, medical oncologists, endocrinologists, gastrointestinal specialists, pathologists, nuclear medicine specialists, surgeons, hematologists, pulmonologists, radiologists, psychologists, general practitioners and nurses to share their opinion. Mapping the access challenges worldwide from both the patients’ and healthcare professionals’ perspectives will help the NET community build a strong argument about global equity.

The survey deadline is October 31, 2019. SCAN does not collect any personal data and is completely anonymous.

Who can participate?

NET PATIENTS & CAREGIVERS TO NET PATIENTS:

http://bit.ly/2JtxDIs

HEALTH CARE PROFESSIONALS BY SPECIALTY RELEVANT TO NETs:

http://bit.ly/2xJ8eE3

Data from the survey would be initially disseminated around World NET Cancer Day, November 10th, 2019. SCAN results will be showcased at medical conferences, published in medical journals, presented at meetings with the decision-makers in the healthcare field to shine light on the gaps in access to early diagnosis, treatment and optimal care globally.

For more information on SCAN, visit https://incalliance.org/scan. #wescan